NSCLC
Breaking into the oncology market
March 10, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Cancer, NSCLC, edwards, gilotrif, oncology
In many ways, the US approval of Boehringer’s Gilotrif for patients with late-stage non-small cell lung cancer (NSCLC) last year …
Roche lung cancer drug fails
March 3, 2014Research and Development, Sales and Marketing Cancer, MetMAb, NSCLC, Roche, Tarceva, avastin
An independent data monitoring committee has told Roche to halt a study of its experimental lung cancer drug MetMab due …
NICE rejects Alimta
February 28, 2014Sales and Marketing Alimta, Cancer, NHS, NICE, NSCLC, lilly, pemetrexed
Eli Lilly is coming to terms with rejection by NICE after the cost watchdog said it would not recommend Alimta …
Roche: NICE guidance ‘perverse’
February 4, 2014Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva
Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …
Pfizer lung cancer drug suffers late-stage setback
January 28, 2014Research and Development, Sales and Marketing Cancer, NSCLC, Pfizer, Roche, Tarceva, dacomitinib
An experimental cancer drug developed by Pfizer has failed in two separate Phase III clinical studies. Dacomitinib is a tyrosine …
GSK has Tafinlar ‘breakthrough’
January 15, 2014Sales and Marketing Cancer, FDA, GSK, NSCLC, Tafinlar
GlaxoSmithKline is on a roll, with its cancer drug Tafinlar given breakthrough therapy designation by the FDA in lung cancer …
New online tool to hear lung cancer patients’ stories
October 29, 2013Medical Communications, Sales and Marketing Boehringer, NSCLC, glcc, lung cancer
The Global Lung Cancer Coalition and Boehringer Ingelheim have teamed-up to increase awareness of the challenges facing individuals and families …
AZ begins late-stage trial of new cancer drug
October 22, 2013Research and Development, Sales and Marketing AstraZeneca, Cancer, NSCLC, selumetinib
AstraZeneca has begun a Phase III study for its investigational lung cancer pill selumetinib in patients with a genetic sub-type …
Boehringer cancer drug impresses
October 1, 2013Research and Development, Sales and Marketing Boehringer, NSCLC, nintedanib
Boehringer Ingelheim has shown off its impressive oncology treatment nintedanib at the European Cancer Congress (ECC) in Amsterdam. The oral triple …
Roche cancer treatment shows promise
September 30, 2013Sales and Marketing MPDL3280A, Merck Serono, NSCLC, Roche
An early-stage oncology treatment has shown encouraging results in smokers with lung cancer, Roche has said in a presentation at …
NICE: final ‘no’ for Xalkori
September 25, 2013Sales and Marketing NICE, NSCLC, Pfizer, Xalkori
Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …
Phoenix from the flames for Lilly cancer drug
August 14, 2013Research and Development, Sales and Marketing NSCLC, lilly, lung cancer, necitumumab
A drug that once looked doomed to fail has shocked analysts by helping late-stage lung cancer patients live longer. Necitumumab …
NSCLC lift for Boehringer
June 4, 2013Research and Development, Sales and Marketing Boehringer, NSCLC
Boehringer’s pipeline has been boosted with the news that its investigational oral triple angiokinase inhibitor nintedanib plus chemotherapy, extends the …
Promising signs for Novartis’ lung cancer drug
June 4, 2013Sales and Marketing ALK+, ASCO, LDK378, NSCLC, Novartis
Targeted lung cancer treatment LDK378 has been shown to help patients with the ALK+ gene mutation in a phase I trial.Novartis’ drug …
Latest content
Five Facts about cardiovascular disease
